VPR-254: an inhibitor of ROR-gamma T with potential utility for the treatment of inflammatory bowel disease

Introduction Retinoic Acid Related Orphan Nuclear Receptor gamma T (ROR gamma T) is a lineage specifying transcription factor for IL-17 expressing cells, which may contribute to the pathogenesis of Inflammatory Bowel Disease (IBD). VPR-254 is a selective in vitro inhibitor of ROR gamma T. Aims The main goals of our study were twofold: (1) To determine if ex vivo treatment with VPR-254 reduced relevant cytokine (IL-17 and IL-21) secretion from colonic strips of mice with colitis; (2) To determine if treatment of mice with VPR-254 attenuated parameters of colitis, using three murine IBD models. Methods VPR-254 was evaluated ex vivo in a colonic strip assay, using tissue from mice with Dextran sulfate sodium (DSS)-induced colitis. In vivo, VPR-254 was evaluated for efficacy in DSS, Trintirobenzenesulfonic acid (TNBS) and Anti-CD40 antibody-induced murine models of colitis. Results VPR-254 reduced the production of key pro-inflammatory cytokines (e.g., IL-17) in ex vivo and in vivo models of colitis. This small molecule inhibitor of ROR gamma T also improved various morphometric and histological parameters associated with three diverse murine models of IBD. Conclusion Our results support the concept that an inhibitor of ROR-gamma T may have potential utility for the treatment of IBD.